NDAINJECTIONINJECTABLEPriority Review
Approved
Jan 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INDOCIN (indomethacin sodium) is a nonsteroidal anti-inflammatory drug (NSAID) administered by injection for acute inflammatory conditions. The mechanism involves inhibition of prostaglandin synthesis through COX enzyme suppression. It is primarily used in neonatal settings for patent ductus arteriosus (PDA) closure and in acute inflammatory indications requiring rapid onset.
LOE Approaching
LOE-approaching injectable product with declining commercial relevance; team likely focused on legacy management and profit extraction rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on INDOCIN offers limited career growth in a LOE-approaching product with minimal innovation pipeline. Roles available are primarily defensive—maintaining compliance, managing generic competition, and optimizing margins rather than driving market expansion or clinical breakthroughs.
Regulatory Affairs SpecialistPharmacovigilance Manager
Worked on INDOCIN at Recordati? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.